Post-prandial insulin lispro vs. human regular insulin in prepubertal children with Type 1 diabetes mellitus

Background. The ELKa system is composed of computer software, with a database of nutrients, and a dedicated USB kitchen scale. It was designed to automatize the everyday calculations of food exchanges and prandial insulin doses. Aim. To investigate the influence of the ELKa on metabolic control in children with type 1 diabetes mellitus (T1DM). Methods. A randomized, parallel, open-label clinical trial involved 106 patients aged <18 years with T1DM, HbA1C≤10%, undergoing intensive insulin therapy, allocated to the intervention group, who used the ELKa (n=53), or the control group (n=53), who used conventional calculation methods. Results. After the 26-week follow-up, the intention-to-treat analysis showed no differences to all endpoints. In per protocol analysis, 22/53 (41.5%) patients reporting ELKa usage for >50% of meals achieved lower HbA1C levels (P=0.002), lower basal insulin amounts (P=0.049), and lower intrasubject standard deviation of blood glucose levels (P=0.023) in comparison with the control. Moreover, in the intervention group, significant reduction of HbA1C level, by 0.55% point (P=0.002), was noted. No intergroup differences were found in the hypoglycemic episodes, BMI-SDS, bolus insulin dosage, and total daily insulin dosage. Conclusions. The ELKa system improves metabolic control in children with T1DM under regular usage. The trial is registered at ClinicalTrials.gov, number NCT02194517.

Download Full-text

729-P: Efficacy and Safety of Mylan Insulin Glargine Products (MYL-1501D) from Two Manufacturing Processes (Process V and Process VI) in Combination with Insulin Lispro in Subjects with Type 1 Diabetes Mellitus

Diabetes ◽

10.2337/db21-729-p ◽

2021 ◽

Vol 70 (Supplement 1) ◽

pp. 729-P

Author(s):

YARON RAITER ◽

THOMAS BLEVINS ◽

BIN SUN ◽

ANOOP CHULLIKANA ◽

GOPINATH RANGANNA ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 1 Diabetes ◽

Insulin Glargine ◽

Type 1 Diabetes Mellitus ◽

Insulin Lispro ◽

Manufacturing Processes ◽

Efficacy And Safety

Download Full-text

In patients with type??1 diabetes mellitus receiving insulin or insulin lispro, pramlintide* reduces postprandial glucose excursions

Inpharma Weekly ◽

10.2165/00128413-200314120-00015 ◽

2003 ◽

Vol &NA; (1412) ◽

pp. 8

Author(s):

&NA;

Keyword(s):

Diabetes Mellitus ◽

Type 1 Diabetes ◽

Type 1 Diabetes Mellitus ◽

Insulin Lispro ◽

Postprandial Glucose

Download Full-text

Evaluation of Safety and Efficacy of Glaritus<sup>®</sup> versus Lantus<sup>®</sup> in Combination with Insulin Lispro among Adults with Type 1 Diabetes Mellitus-Phase IV Study

Open Journal of Endocrine and Metabolic Diseases ◽

10.4236/ojemd.2017.74011 ◽

2017 ◽

Vol 07 (04) ◽

pp. 111-125 ◽

Cited By ~ 1

Author(s):

Gaurav Puppalwar ◽

Sandesh Sawant ◽

Bhimsen Silgiri ◽

Kirti Shukla ◽

Hanmant Barkate

Keyword(s):

Diabetes Mellitus ◽

Type 1 Diabetes ◽

Type 1 Diabetes Mellitus ◽

Insulin Lispro ◽

Safety And Efficacy ◽

Phase Iv

Download Full-text

Nephrotic syndrome co-existing with type 1 diabetes in a 12-year-old boy: Case report and literature review

SAGE Open Medical Case Reports ◽

10.1177/2050313x19827734 ◽

2019 ◽

Vol 7 ◽

pp. 2050313X1982773 ◽

Cited By ~ 1

Author(s):

Noor S Bawahab ◽

Osama Y Safdar ◽

Sarah A Nagadi ◽

Asalh T Saeedi ◽

Raghad W Mohammed Hussain

Keyword(s):

Diabetes Mellitus ◽

Type 1 Diabetes ◽

Nephrotic Syndrome ◽

Type 1 Diabetes Mellitus ◽

Pediatric Nephrology ◽

Regular Insulin ◽

Response To Treatment ◽

Low Protein ◽

The Relationship

Occurrence of early nephrotic syndrome in type 1 diabetes mellitus patients is extremely rare. Herein, we report the case of a 12-year-old boy who presented to our pediatric nephrology clinic with generalized edema. He had been diagnosed with type 1 diabetes mellitus at age 9 and had been treated with regular insulin. Examinations revealed normal kidney function, hypoalbuminemia, proteinuria (4+), hyperlipidemia, and low protein-to-creatinine ratio. The patient was diagnosed with idiopathic nephrotic syndrome and was empirically administered prednisolone for 12 weeks. Subsequently, prednisolone was tapered over 10–12 weeks. The patient showed good response to treatment. In conclusion, co-existence of nephrotic syndrome and type 1 diabetes mellitus may suggest an immunological basis; therefore, further studies are needed to investigate the relationship between these two conditions.

Download Full-text